KR102265159B1 - 수술적 절제 후 간세포암종 환자를 치료하기 위한 약제의 제조에서 황산화된 올리고당류의 용도 - Google Patents

수술적 절제 후 간세포암종 환자를 치료하기 위한 약제의 제조에서 황산화된 올리고당류의 용도 Download PDF

Info

Publication number
KR102265159B1
KR102265159B1 KR1020197028654A KR20197028654A KR102265159B1 KR 102265159 B1 KR102265159 B1 KR 102265159B1 KR 1020197028654 A KR1020197028654 A KR 1020197028654A KR 20197028654 A KR20197028654 A KR 20197028654A KR 102265159 B1 KR102265159 B1 KR 102265159B1
Authority
KR
South Korea
Prior art keywords
patients
hcc
medicament
involvement
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197028654A
Other languages
English (en)
Korean (ko)
Other versions
KR20190120339A (ko
Inventor
스탠리 창
콴-랑 라이
Original Assignee
메디젠 바이오테크놀로지 코프
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디젠 바이오테크놀로지 코프 filed Critical 메디젠 바이오테크놀로지 코프
Publication of KR20190120339A publication Critical patent/KR20190120339A/ko
Application granted granted Critical
Publication of KR102265159B1 publication Critical patent/KR102265159B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020197028654A 2017-03-01 2018-02-24 수술적 절제 후 간세포암종 환자를 치료하기 위한 약제의 제조에서 황산화된 올리고당류의 용도 Active KR102265159B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762465170P 2017-03-01 2017-03-01
US62/465,170 2017-03-01
US201762504552P 2017-05-11 2017-05-11
US62/504,552 2017-05-11
US201762551770P 2017-08-29 2017-08-29
US62/551,770 2017-08-29
PCT/CN2018/077105 WO2018157762A1 (en) 2017-03-01 2018-02-24 Use of sulfated oligosaccharides in the manufacture of a medicament for treating patients with hepatocellular carcinoma after surgical resection

Publications (2)

Publication Number Publication Date
KR20190120339A KR20190120339A (ko) 2019-10-23
KR102265159B1 true KR102265159B1 (ko) 2021-06-17

Family

ID=63357147

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197028654A Active KR102265159B1 (ko) 2017-03-01 2018-02-24 수술적 절제 후 간세포암종 환자를 치료하기 위한 약제의 제조에서 황산화된 올리고당류의 용도

Country Status (6)

Country Link
US (1) US10842804B2 (cg-RX-API-DMAC7.html)
JP (1) JP6948080B2 (cg-RX-API-DMAC7.html)
KR (1) KR102265159B1 (cg-RX-API-DMAC7.html)
CN (1) CN110381953A (cg-RX-API-DMAC7.html)
TW (1) TWI693071B (cg-RX-API-DMAC7.html)
WO (1) WO2018157762A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113160911A (zh) * 2021-02-26 2021-07-23 杭州臻合健康科技有限公司 一种用于术前肝功能耐受性分析的评估系统
CN117476246B (zh) * 2023-12-25 2024-04-19 福建大数据一级开发有限公司 基于多类型复发事件的患者生存分析方法、介质及装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012167434A1 (zh) 2011-06-09 2012-12-13 基亚生物科技股份有限公司 用于抑制肝癌复发、恶化或转移之医药组成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101156273B1 (ko) * 2004-03-04 2012-06-13 프로젠 파마슈티칼즈 리미티드 황산화 올리고사카라이드 유도체

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012167434A1 (zh) 2011-06-09 2012-12-13 基亚生物科技股份有限公司 用于抑制肝癌复发、恶化或转移之医药组成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Hepatology, Vol. 50, pp. 958-968 (2009)*
Journal of International Pharmacoceutical Research, Vol. 35, No. 6, pp. 411-414 (2008)

Also Published As

Publication number Publication date
US20180250317A1 (en) 2018-09-06
US10842804B2 (en) 2020-11-24
JP2020509035A (ja) 2020-03-26
JP6948080B2 (ja) 2021-10-13
TWI693071B (zh) 2020-05-11
CN110381953A (zh) 2019-10-25
WO2018157762A1 (en) 2018-09-07
TW201840324A (zh) 2018-11-16
KR20190120339A (ko) 2019-10-23

Similar Documents

Publication Publication Date Title
US20250154274A1 (en) Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment
Camidge et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-met protein–overexpressing advanced nonsquamous EGFR-wildtype non–small cell lung cancer in the phase II LUMINOSITY trial
Anstee et al. Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design
KR102610764B1 (ko) 암을 치료하기 위한 카보잔티닙 및 아테졸리주맙의 조합
EP4149455A1 (en) Atr inhibitors for the treatment of cancer
Sharp et al. Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis
JP2013067645A (ja) 転移性乳癌の治療
CN108602892A (zh) 使用抗-pd-1抗体和另一种抗癌剂的组合治疗肺癌
CN119923259A (zh) 治疗具有激活型fgfr3基因改变的实体瘤的方法
Akamatsu et al. Pembrolizumab plus amrubicin in patients with relapsed SCLC: multi-institutional, single-arm phase 2 study
US20260098087A1 (en) Dosages of emactuzumab
CN120731227A (zh) 使用抗ctla4抗体治疗结直肠癌的方法
Zhang et al. Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging
US10842804B2 (en) Muparfostat for use in treating patients with hepatitis virus-related hepatocellular carcinoma after surgical resection
Prawira et al. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001)
Cui et al. Real-world clinical outcomes of anticancer treatments in patients with advanced melanoma in China: retrospective, observational study
Stefanou et al. Subcutaneous trastuzumab combined with pertuzumab and docetaxel as first-line treatment of advanced HER2-positive breast cancer
Zeng et al. Adebrelimab combined with anlotinib plus hepatic arterial infusion chemotherapy or intravenous chemotherapy for first-line treatment of advanced biliary tract cancer: protocol for a randomized open-label clinical study
Fujii et al. ENVELOPE: enfortumab vedotin in patients with advanced small bowel adenocarcinoma refractory or intolerant to platinum-based therapy—phase II investigator-initiated trial (NCCH2412/MK015)
KR20240162547A (ko) 화학요법과 조합하여 항-pd-l1 항체를 사용하여 담도암을 치료하는 방법
TW202529802A (zh) 胃癌和/或胃食管結合部癌的治療
Gouveia et al. Immunotherapy-Associated Autoimmune Hemolytic Anemia: Two Case Reports and a Literature Review
WO2025179012A1 (en) Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens
CN121843965A (zh) 靶向psma和效应细胞抗原的肿瘤激活抗体相关的组合物和方法
Leemans Short title NeoNivo EudraCT number 2018-002643-28 Version 9 Date 11-12-2019 Principal investigators C. Willemien Menke-van der Houven van Oordt, MD PhD

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A302 Request for accelerated examination
PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6